Samalin L - Search Results

1

Measuring the Patient Experience of Mental Health Care: A Systematic and Critical Review of Patient-Reported Experience Measures.

Fernandes S, Fond G, Zendjidjian XY, Baumstarck K, Lançon C, Berna F, Schurhoff F, Aouizerate B, Henry C, Etain B, Samalin L, Leboyer M, Llorca PM, Coldefy M, Auquier P, Boyer L; French PREMIUM Group. Fernandes S, et al. Among authors: samalin l. Patient Prefer Adherence. 2020 Nov 3;14:2147-2161. doi: 10.2147/PPA.S255264. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 33192054 Free PMC article. Review.

2

[Validated care programs for patients with functional neurological disorders].

Rauline G, Hingray C, Carle-Toulemonde G, Hubsch C, El Hage W, Conejero I, Samalin L, Garcin B, Gharib A. Rauline G, et al. Among authors: samalin l. Encephale. 2023 Aug;49(4S):S33-S41. doi: 10.1016/j.encep.2023.06.005. Epub 2023 Jul 1. Encephale. 2023. PMID: 37400332 Review. French.

3

[Recommandations to facilitate the discontinuation of valproate in women of childbearing age].

Samalin L, Belzeaux R. Samalin L, et al. Encephale. 2023 Aug;49(4):440-441. doi: 10.1016/j.encep.2023.03.006. Epub 2023 Apr 29. Encephale. 2023. PMID: 37127483 French. No abstract available.

4

Optimizing treatment of schizophrenia to minimize relapse.

Samalin L, Blanc O, Llorca PM. Samalin L, et al. Expert Rev Neurother. 2010 Feb;10(2):147-50. doi: 10.1586/ern.09.147. Expert Rev Neurother. 2010. PMID: 20136373 Review. No abstract available.

5

Adherence to guidelines by French psychiatrists in their real world of clinical practice.

Samalin L, Guillaume S, Auclair C, Llorca PM. Samalin L, et al. J Nerv Ment Dis. 2011 Apr;199(4):239-43. doi: 10.1097/NMD.0b013e3182125d4c. J Nerv Ment Dis. 2011. PMID: 21451347

6

Clinical potential of lurasidone in the management of schizophrenia.

Samalin L, Garnier M, Llorca PM. Samalin L, et al. Ther Clin Risk Manag. 2011;7:239-50. doi: 10.2147/TCRM.S12701. Epub 2011 Jun 27. Ther Clin Risk Manag. 2011. PMID: 21753886 Free PMC article.

7

Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?

Samalin L, Guillaume S, Courtet P, Abbar M, Lancrenon S, Llorca PM. Samalin L, et al. Compr Psychiatry. 2013 May;54(4):309-20. doi: 10.1016/j.comppsych.2012.10.001. Epub 2012 Nov 13. Compr Psychiatry. 2013. PMID: 23153855 Review.

8

Asenapine in bipolar I disorder: evidence and place in patient management.

Samalin L, Charpeaud T, Llorca PM. Samalin L, et al. Ther Adv Chronic Dis. 2013 Jan;4(1):5-14. doi: 10.1177/2040622312468933. Ther Adv Chronic Dis. 2013. PMID: 23342243 Free PMC article.

9

[Mixed states].

Llorca PM, Charpeaud T, Samalin L. Llorca PM, et al. Among authors: samalin l. Encephale. 2012 Dec;38 Suppl 4:S179-85. doi: 10.1016/S0013-7006(12)70097-0. Encephale. 2012. PMID: 23395234 Review. French.

10

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES).

Llorca PM, Lancon C, Blanc O, de Chazeron I, Samalin L, Caci H, Lesturgeon JA, Bayle FJ. Llorca PM, et al. Among authors: samalin l. Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):171-8. doi: 10.1007/s00406-013-0416-1. Epub 2013 Jun 15. Eur Arch Psychiatry Clin Neurosci. 2014. PMID: 23771406

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page